A case of successful conversion from everolimus to surgical resection of a giant pancreatic neuroendocrine tumor

被引:7
作者
Asahi Sato
Toshihiko Masui
Nao Sankoda
Kenzo Nakano
Yuichiro Uchida
Takayuki Anazawa
Kyoichi Takaori
Yoshiya Kawaguchi
Shinji Uemoto
机构
[1] Kyoto University,Division of Hepato
关键词
Neuroendocrine tumor; Everolimus; Sunitinib malate; Ga-DOTATOC-PET/CT;
D O I
10.1186/s40792-017-0361-8
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 65 条
[1]  
Metz DC(2008)Gastrointestinal neuroendocrine tumors Gastroenterology 135 1469-92
[2]  
Jensen RT(2010)Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan J Gasroenterol 45 234-43
[3]  
Ito T(2011)Prognostic factors and survival in patients with neuroendocrine tumors of the pancreas Tumour Biol 32 697-705
[4]  
Sasano H(2011)Pancreatic cancer Lancet 378 607-20
[5]  
Tanaka M(2011)Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 514-23
[6]  
Osamura RY(2011)Sunitinib malate for the treatment of pancreatic neuroendocrine tumors N Engl J Med 364 501-13
[7]  
Sasaki I(2015)A case of pancreatic neuroendocrine tumor with tumor embolus in the portal vein resected surgically after neoadjuvant chemotherapy J Jpn Surg Assoc 76 885-9
[8]  
Kimura W(2009)Targeting the mTOR signaling network for cancer therapy J Clin Oncol 27 2278-87
[9]  
Wang DS(2011)DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors Science 331 1199-203
[10]  
Zhang DS(2013)Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience Cancer Res 73 1449-53